Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SNDX Stock Forecast 2026-2027
$16.96
Current Price
$1.54B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SNDX Price Targets
+236.1%
To High Target of $57.00
+118.2%
To Median Target of $37.00
+71.0%
To Low Target of $29.00
SNDX Price Momentum
-7.8%
1 Week Change
-21.1%
1 Month Change
+52.9%
1 Year Change
-19.3%
Year-to-Date Change
-33.7%
From 52W High of $25.59
+97.6%
From 52W Low of $8.59
📊 TOP ANALYST CALLS
Did SNDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Syndax is one of their latest high-conviction picks.
Latest SNDX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, SNDX has a bullish consensus with a median price target of $37.00 (ranging from $29.00 to $57.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $16.96, the median forecast implies a 118.2% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SNDX Analyst Ratings
13
Buy
0
Hold
0
Sell
SNDX Price Target Range
Low
$29.00
Average
$37.00
High
$57.00
Current: $16.96
Latest SNDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SNDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $40.00 |
| May 13, 2026 | UBS | Buy | Maintains | $N/A | |
| May 1, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 1, 2026 | Goldman Sachs | Buy | Maintains | $N/A | |
| Mar 31, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 30, 2026 | Jefferies | Faisal Khurshid | Buy | Assumes | $40.00 |
| Mar 9, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Mar 2, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 27, 2026 | Mizuho | Mara Goldstein | Outperform | Maintains | $600.00 |
| Dec 9, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Nov 24, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 12, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 4, 2025 | UBS | Buy | Maintains | $N/A | |
| Nov 4, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Oct 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 27, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Oct 16, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Assumes | $40.00 |
| Sep 19, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 10, 2025 | Stifel | Bradley Canino | Buy | Reinstates | $44.00 |
| Sep 5, 2025 | Goldman Sachs | Buy | Maintains | $N/A |
Syndax Pharmaceuticals Inc. (SNDX) Competitors
The following stocks are similar to Syndax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Syndax Pharmaceuticals Inc. (SNDX) Financial Data
Syndax Pharmaceuticals Inc. has a market capitalization of $1.54B with a P/E ratio of -5.2x. The company generates $217.17M in trailing twelve-month revenue with a -112.0% profit margin.
Revenue growth is +223.6% quarter-over-quarter, while maintaining an operating margin of -52.7% and return on equity of -189.5%.
Valuation Metrics
Market Cap
$1.54B
Enterprise Value
$1.52B
P/E Ratio
-5.2x
PEG Ratio
0.1x
Price/Sales
7.1x
Growth & Margins
Revenue Growth (YoY)
+223.6%
Gross Margin
+95.9%
Operating Margin
-52.7%
Net Margin
-112.0%
EPS Growth
+223.6%
Financial Health
Cash/Price Ratio
+24.0%
Current Ratio
5.5x
Debt/Equity
829.8x
ROE
-189.5%
ROA
-25.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Syndax Pharmaceuticals Inc. (SNDX) Business Model
About Syndax Pharmaceuticals Inc.
What They Do
Develops innovative cancer therapies for unmet needs.
Business Model
Syndax Pharmaceuticals operates by developing and commercializing specialized oncology therapies, generating revenue from the sales of its approved products like Revuforj. The company also leverages proprietary platforms to enhance drug development and patient care, targeting healthcare providers and patients in the oncology sector.
Additional Information
Founded in 2005 and based in New York, Syndax focuses on addressing critical gaps in cancer treatment, particularly for acute leukemias and related hematologic malignancies. By combining research and commercial distribution, the company positions itself as a key player in the biotechnology industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
270
CEO
Mr. Michael A. Metzger M.B.A.
Country
United States
IPO Year
2016
Website
syndax.comSyndax Pharmaceuticals Inc. (SNDX) Latest News & Analysis
Latest News
Quick Summary
A pooled analysis of 24 acute leukemia patients resuming revumenib post-transplant shows a 2-year overall survival rate of 90%, significantly higher than the historical benchmark of 51%.
Why It Matters
The high 2-year overall survival rate of 90% for leukemia patients resuming revumenib post-transplant suggests strong efficacy, potentially boosting investor confidence in the drug's market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Syndax Pharmaceuticals has secured $250 million through privately negotiated subscription agreements for 2.25% Convertible Senior Notes due 2031. Closing is expected on June 10, 2026.
Why It Matters
Syndax's $250 million convertible notes indicate confidence in future growth, potentially diluting shares but also funding cancer therapy advancements, impacting long-term valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Syndax Pharmaceuticals granted stock options for 66,700 shares to four new employees under its 2023 Inducement Plan, vesting over four years contingent on continued employment.
Why It Matters
The grant of stock options to new employees indicates Syndax Pharmaceuticals' commitment to attracting talent, which can drive innovation and growth, positively impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
7 days ago
Quick Summary
Syndax Pharmaceuticals will host an R&D Day on July 14, 2026, in New York City, featuring presentations from its management and key opinion leaders.
Why It Matters
Syndax Pharmaceuticals' R&D Day could signal new developments in cancer therapies, potentially impacting stock performance and attracting investor interest in innovative treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
An oral presentation will showcase positive results in 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia treated with revumenib after transplant.
Why It Matters
Positive outcomes in leukemia patients receiving revumenib post-transplant suggest potential market growth and increased investor confidence in the biotech's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) will have CEO Michael A. Metzger and management participate in upcoming investor conferences, highlighting the company's focus on cancer therapies.
Why It Matters
Syndax Pharmaceuticals' participation in investor conferences signals potential growth opportunities, showcasing their commitment to transparency and engaging with the investment community.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SNDX Stock
What is Syndax Pharmaceuticals Inc.'s (SNDX) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Syndax Pharmaceuticals Inc. (SNDX) has a median price target of $37.00. The highest price target is $57.00 and the lowest is $29.00.
Is SNDX stock a good investment in 2026?
According to current analyst ratings, SNDX has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SNDX stock?
Wall Street analysts predict SNDX stock could reach $37.00 in the next 12 months. This represents a 118.2% increase from the current price of $16.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Syndax Pharmaceuticals Inc.'s business model?
Syndax Pharmaceuticals operates by developing and commercializing specialized oncology therapies, generating revenue from the sales of its approved products like Revuforj. The company also leverages proprietary platforms to enhance drug development and patient care, targeting healthcare providers and patients in the oncology sector.
What is the highest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
The highest price target for SNDX is $57.00 from at , which represents a 236.1% increase from the current price of $16.96.
What is the lowest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
The lowest price target for SNDX is $29.00 from at , which represents a 71.0% increase from the current price of $16.96.
What is the overall SNDX consensus from analysts for Syndax Pharmaceuticals Inc.?
The overall analyst consensus for SNDX is bullish. Out of 5 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are SNDX stock price projections?
Stock price projections, including those for Syndax Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:48 AM UTC